"Is this for humans or animals?"
At the 91st China International Medical Equipment Fair (CMEF) international exhibition area, ZentMed's human tumor microwave ablation device and Zhenchong Medical's animal-specific tumor microwave ablation device were exhibited side by side, attracting a group of "soul-searching questions" from domestic and foreign buyers.
Upon learning that the two companies share the same technology and are focusing on the human and pet medical markets respectively, a Nepalese distributor gave a thumbs up: "This business logic is so cool!"

At the International Pet Health Forum, the Marketing Director of Zhenchong Medical delivered a speech entitled "Case Studies and Market Outlook of Microwave Ablation Instrument for Pet Tumor Treatment," using three "counterintuitive" conclusions to highlight the enthusiasm for cooperation.

1. "Smaller, More Difficult": The essence of "smaller, more difficult" is that it places higher demands on pet medical technology—on the battlefield at the millimeter level, it is necessary to completely eradicate tumors while protecting fragile structural functions. The innovation of microwave ablation technology is making "non-invasive cure for small tumors" a reality, redefining the precision and warmth of pet medical care.

2. "The older, the more valuable": The essence of "the older, the more valuable" is that technological innovation transforms aging pets from "medical orphans" into "high-value assets." By reducing risks, improving the experience, and extending the quality of life, minimally invasive treatment not only revitalizes the existing market but also creates high-end incremental demand—this is a new business paradigm in the phenomenon of pet aging where technology and emotion work together.

3. "Niche Essentials": These are life-or-death needs hidden in the "hidden corners" of pet life. For example, common pet tumors such as mammary tumors and perianal adenomas have a potential treatment volume exceeding 5 million cases globally each year. Microwave ablation for animal tumors can treat tumors while preserving the pet's physiological tissues, ensuring no impact on the pet's post-operative quality of life.

"Our technology is not a replacement for surgery, but rather a creation of new treatment grading standards." By the end of the speech, three domestic and international distributors in the audience had already raised their letters of intent for cooperation.

On-site confrontation: The international buyer's probing question

Exploring cultural treasures

Southeast Asian animal protection organization: "Can we afford to support stray cats and dogs?"
The marketing director of Zhenchong Medical revealed data showing that the cost of consumables is lower than that of the human version, and can be further reduced through public welfare cooperation.

College of Veterinary Medicine: "Can it be used for teaching?"
The marketing director of Zhenchong Medical provided on-site guidance to the teacher who asked questions, using pig liver to simulate animal tumor ablation, and successfully obtained ablation data within 30 seconds.

Future Battleground: Who is vying for the billion-dollar blue ocean of pet tumor treatment?

The global pet population has reached 2.300 million cases; cancer incidence rate is rising year by year. Key signals received so far:
• European animal hospitals begin establishing "minimally invasive oncology departments"
• US pet insurance adds "microwave ablation" reimbursement clause 

• Japanese chain pet stores pilot integrated "early screening + ablation" service Zhenchong Medical adheres to the spirit of open and flexible cooperation and is willing to work together with friends who are committed to developing the animal tumor ablation market to develop the blue ocean market of minimally invasive treatment for animal tumors!